5-氯甲基-2-三氟甲基-1,3,4-噁二唑 | 723286-98-4

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氯甲基-2-三氟甲基-1,3,4-噁二唑
• 中文别名: 2-(氯甲基)-5-(三氟甲基)-1,3,4-噁二唑；2-(氯甲基)-5-(三氟甲基)-1,3,4-恶二唑;；5-氯甲基-2-三氟甲基-1,3,4-二唑；2-(氯甲基)-5-(三氟甲基)-1,3,4-恶二唑
• 英文名称: 2-trifluoromethyl-1,3,4-oxadiazol-5-ylmethyl chloride
• 英文别名: 5‑(chloromethyl)‑2‑(trifluoromethyl)‑1,3,4 oxadiazole；2-(chloromethyl)-5-(trifluoromethyl)-1,3,4-oxadiazole；2-chloromethyl-5-trifluoromethyl-1,3,4-oxadiazole；5-(TRIFLUOROMETHYL)-2-(CHLOROMETHYL)-1,3,4-OXADIAZOLE；5-(trifluoromethyl)-2-(chloromethyl)-l,3,4-oxadiazole；2-chloromethyl-5-(trifluoromethyl)-1,3,4-oxadiazole
• CAS: 723286-98-4
• 化学式: C₄H₂ClF₃N₂O
• mdl: MFCD09699166
• 分子量: 186.521
• InChiKey: GPXSXZGMVOSWMN-UHFFFAOYSA-N

物化性质

• 沸点：
  55-60 °C(Press: 10 Torr)
• 密度：
  1.555±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（可溶）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314
• 储存条件：
  2~8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(Chloromethyl)-2-(trifluoromethyl)-1,3,4-oxadiazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(Chloromethyl)-2-(trifluoromethyl)-1,3,4-oxadiazole
CAS number: 723286-98-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H2ClF3N2O
Molecular weight: 186.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯甲基-2-三氟甲基-1,3,4-噁二唑 、 N-苄基乙二胺 以 甲醇 为溶剂， 反应 1.0h， 以67%的产率得到N'-[(2Z)-4-benzylpiperazin-2-ylidene]-2,2,2-trifluoroacetohydrazide
  参考文献：
  名称：

  Synthesis of [1,2,4]Triazolo[4,3-α]piperazines via Highly Reactive Chloromethyloxadiazoles

  摘要：

  A concise, modular approach for the synthesis of [1,2,4]triazolo[4,3-alpha]piperazines via condensation of highly reactive chloromethyloxadiazoles with ethylenediamines is described. NMR studies of this reaction provide evidence that suggests a novel activation mechanism for electrondeficient chloromethyloxadiazoles.

  DOI：

  10.1021/ol0474406
• 作为产物：
  描述：

  1-(氯乙酰基)-2-(三氟乙酰基)肼 在 三氯氧磷 作用下， 以 乙腈 为溶剂， 以61 %的产率得到5-氯甲基-2-三氟甲基-1,3,4-噁二唑
  参考文献：
  名称：

  新型三唑并[4,3-a]吡嗪衍生物的合成及抗菌活性

  摘要：

  传染病对人类健康构成重大挑战，迫切需要开发具有优异抗菌活性的新型抗菌药物。合成了一系列新型三唑并[4,3-a]吡嗪衍生物，并利用熔点、1H和13C核磁共振波谱、质谱和元素分析等技术对其结构进行了表征。使用微肉汤稀释法评价所有合成的化合物的体外抗菌活性。在所有测试的化合物中，一些化合物对革兰氏阳性金黄色葡萄球菌和革兰氏阴性大肠杆菌菌株均表现出中等至良好的抗菌活性。特别是，化合物2e表现出优异的抗菌活性（MIC：对金黄色葡萄球菌的MIC为32 μg/mL，对大肠杆菌的MIC为16 μg/mL），与一线抗菌剂氨苄青霉素相当。此外，还初步研究了三唑并[4,3-a]吡嗪衍生物的构效关系。

  DOI：

  10.3390/molecules28237876

文献信息

• [EN] AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] AMINOCYCLOHEXANES EN TANT QU'INHIBITEURS DE DIPEPTIDYL PEPTIDASE-IV POUR LE TRAITEMENT OU LA PRÉVENTION DE DIABÈTES
  申请人：MERCK & CO INC

  公开号：WO2006009886A1

  公开（公告）日：2006-01-26

  The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代氨基环己烷，它们是二肽基肽酶-IV酶（'DPP-IV抑制剂'）的抑制剂，并且在治疗或预防涉及二肽基肽酶-IV酶的疾病中具有用处，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及二肽基肽酶-IV酶的这类疾病中使用这些化合物和组合物。
• [EN] 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE 3-AMINO-4-PHENYLBUTANOIQUE ACIDE UTILISES EN TANT QU'INHIBITEURS DE DIPEPTIDYL PEPTIDASE POUR LE TRAITEMENT OU LA PREVENTION DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2004058266A1

  公开（公告）日：2004-07-15

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist
  作者：Seon-Mi Kim、Minhee Lee、So Young Lee、Euisun Park、Soo-Min Lee、Eun Jeong Kim、Min Young Han、Taekyung Yoo、Jihyae Ann、Suyoung Yoon、Jiyoun Lee、Jeewoo Lee

  DOI：10.1021/acs.jmedchem.6b01071

  日期：2016.10.13

  We developed a compound library for orally available gonadotropin-releasing hormone (GnRH) receptor antagonists that were based on a uracil scaffold. On the basis of in vitro activity and CYP inhibition profile, we selected 18a (SKI2496) for further in vivo studies. Compound 18a exhibited more selective antagonistic activity toward the human GnRH receptors over the GnRHRs in monkeys and rats, and this

  我们开发了基于尿嘧啶支架的口服促性腺激素释放激素（GnRH）受体拮抗剂的化合物库。根据体外活性和CYP抑制谱，我们选择18a（SKI2496）进行进一步的体内研究。与猴子和大鼠中的GnRHR相比，化合物18a对人GnRH受体具有更高的选择性拮抗活性，并且该化合物还对GnRH介导的信号传导途径具有抑制作用。与临床上最先进的化合物Elagolix相比，对18a的药代动力学和药效学评估显示出更高的生物利用度和优异的促性腺激素抑制活性。考虑到18a表现出对h GnRHRs的强效和选择性拮抗活性以及良好的药代动力学特征，我们认为18a可能代表口服激素治疗的有希望的候选者。
• Design, synthesis, biological evaluation and computational study of novel triazolo [4,3-a]pyrazin analogues
  作者：Divya J. Jethava、Prachi T. Acharya、Mahesh S. Vasava、Manoj N. Bhoi、Zeel A. Bhavsar、Sanjay K. Rathwa、Dhanji P. Rajani、Hitesh D. Patel

  DOI：10.1016/j.molstruc.2019.01.091

  日期：2019.5

  3-a]pyrazin analogues are of interest due to their potential activity against various infectious and non-infectious disease. In search of suitable potent drug candidate, we report here the design, synthesis, characterization, biological activities and computation study of novel triazolo [4,3-a]pyrazin analogues. The synthesized molecules were characterized by various spectroscopic studies such as IR

  摘要 三唑并 [4,3-a] 吡嗪类似物因其对各种传染性和非传染性疾病的潜在活性而受到关注。为了寻找合适的有效候选药物，我们在此报告了新型三唑并 [4,3-a] 吡嗪类似物的设计、合成、表征、生物活性和计算研究。合成的分子通过各种光谱研究进行表征，如红外、质谱、1H NMR、13C NMR 和元素分析。评估了新合成的化合物的体外生物活性，例如分别对恶性疟原虫、H37Rv、各种细菌和真菌菌株的抗疟疾、抗结核、抗菌和抗真菌活性。用来自恶性疟原虫的酶天冬氨酸蛋白酶酶原 proplasmepsin II 进行分子对接研究，以分析它们在天冬氨酸蛋白酶活性位点的结合方向。对最佳对接复合物进行分子动力学模拟，以说明这些复合物的稳定性以及模拟轨迹期间最突出的相互作用。我们还计算了所有合成化合物的 ADMET 特性，以预测用于选择化合物活性和生物利用度的药代动力学特性。对最佳对接复合物进行分子动力学模拟，以
• SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF
  申请人：BAYER AKTIENGESELLSCHAFT

  公开号：US20190160048A1

  公开（公告）日：2019-05-30

  The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.

  该申请涉及新颖的取代5,6,7,8-四氢[1,2,4]三唑并[4,3-a]吡啶-3(2H)-酮和2,5,6,7-四氢-3H-吡咯[2,1-c][1,2,4]三唑-3-酮，其制备方法，以及其单独或组合使用用于治疗和/或预防疾病，以及其用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部炎症性疾病。